Overview

Safety and Efficacy Study of Rifalazil for the Treatment of Chlamydia Trachomatis Infection in Women

Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
This study will test the safety and effectiveness of an investigational antibiotic drug, rifalazil for the treatment of uncomplicated genital Chlamydia trachomatis infection. This study will examine the effects of 25 milligram of rifalazil compared with azithromycin 1 gram, which will be given as a single dose to women who have genital chlamydial infection.
Phase:
Phase 2
Details
Lead Sponsor:
ActivBiotics Pharma, LLC
Treatments:
Azithromycin
KRM 1648
Rifamycins